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Edited by Veli-Pekka LehtoAbstract We previously found that bikunin (bik), a Kunitz-type
protease inhibitor, suppresses transforming growth factor-b1
(TGF-b1)–stimulated expression of urokinase-type plasminogen
activator (uPA) in human ovarian cancer cells that lack
endogenous bik. In the present study, we tried to elucidate the
mechanism by which bik also inhibits plasminogen activator
inhibitor type-1 (PAI-1) and collagen synthesis using human
ovarian cancer cells. Here, we show that (a) there was an
enhanced production of both uPA and PAI-1 in HRA cells in
response to TGF-b1; (b) the overexpression of bik in the cells or
exogenous bik results in the inhibition of TGF-b1 signaling as
measured by phosphorylation of the downstream signaling
eﬀector Smad2, nuclear translocation of Smad3, and production
of PAI-1 and collagen; (c) bik neither decreased expression of
TGF-b receptors (TbRI and TbRII) in either cell types nor
altered the speciﬁc binding of 125I TGF-b1 to the cells, indicating
that the eﬀects of bik in these cells are not mediated by ligand
sequestration; (d) TbRI and TbRII present on the same cells
exclusively form aggregates in TGF-b1-stimulated cells; (e) co-
treatment of TGF-b1–stimulated cells with bik suppresses TGF-
b1–induced complex formation of TbRI and TbRII; and (f) a
chondroitin-4-sulfate side chain-deleted bik (deglycosylated bik)
does not inhibit TGF-b1 signaling or association of type I/type II
receptor. We conclude that glycosylated bik attenuates TGF-b1–
elicited signaling cascades in cells possibly by abrogating the
coupling between TbRI and TbRII and that this probably
provides the mechanism for the suppression of uPA and PAI-1
expression.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Bikunin is a secreted Kunitz-type protease inhibitor with a
postulated role in protease inhibition [1]. Our laboratory has
been studying the function and mechanism of bikunin (bik) on
the suppression of the invasive capacity of tumor cells [2–4].
We have proposed that bik is a main participant in the inhi-
bition of tumor cell invasion and metastasis possibly through
both direct inhibition of cell-associated plasmin activity and
suppression of urokinase-type plasminogen activator (uPA)
expression [2].
During the search for novel proteins interacting with bik, we
identiﬁed at least two types of cell-associated binding proteins,
the 40-kDa link protein (LP) and a 45 kDa protein. The former
belongs to the hyaluronan (HA)-binding protein. The latter is
a membrane-associated putative receptor for bik (bik-R) [3–5].
We postulate that LP is an extracellular matrix-binding protein
and acts as a ‘‘sink’’ for bik. The diverse roles proposed for LP
can largely be understood as a manifestation of HA stabil-
ization in the pericellular matrix [5,6]. We have established that
LP interacts with the NH2-terminal domain of bik, while bik-
R recognizes the chondroitin-4-sulfate side chain of bik [3,4].
Analysis of binding of native bik and chondroitin-4-sulfate-
deleted bik (deglycosylated bik) to the cells showed that the
low aﬃnity binding site is LP and the high aﬃnity binding site
is bik-R [4]. Our previous publications indicated that binding
of bik to its binding sites on the cell surface is associated with
an inhibition of protein kinase C translocation and activation
[2,7,8]. More recently, we reported that bik markedly sup-
presses the cell invasion possibly through negative regulation
of mitogen-activated protein kinase-dependent mechanisms
and subsequent suppression of uPA expression, and that bik
must bind to both of the bik-binding proteins (LP and bik-R)
to eﬀectively suppress the upregulation of uPA expression
[2,4,7,8]. Thus, bik could act as a negative modulator of the
invasive cells.
CD44 is the major cell-surface receptor for HA [9]. Since one
of the bik-binding proteins is LP, which is apparently held at
the cell surface by HA [6], it is reasonable to think that CD44
would be involved in this bik-mediated complex at the cell
surface. The previous results showed that engagement of bik-Rblished by Elsevier B.V. All rights reserved.
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itate inhibition of cell stimulation by suppression of CD44
activation (that is CD44 clustering), which ﬁnally leads to re-
duction of uPA expression [10].
To better understand the function of bik, we studied its
biological eﬀects in human ovarian cancer HRA and SKOV-
3 cells. We have previously demonstrated that these cells
have no endogenous bik expression and that increased
expression of bik in them inhibits transforming growth
factor-b (TGF-b) signaling [11,12]. TGF-b1 is an essential
regulator of development, cell proliferation, and matrix de-
position [13–15] and is initiated by the binding of TGF-b to
TGF-b receptor type II (TbRII). This is followed by the
formation and stabilization of TbRI–TbRII complexes,
transphosphorylation of TbRI by TbRII, and phosphoryla-
tion of the receptor-associated cytoplasmic eﬀector molecules
Smad2 and Smad3 by TbRI [13,15]. Studies presented in this
report were designed to investigate the eﬀects of bik on
TGF-b1-mediated stimulation of uPA, plasminogen activator
inhibitor type-1 (PAI-1) and collagen expression in HRA
and SKOV-3 human ovarian cancer cells and to elucidate
the mechanism(s) involved in this modulation. In addition,
human skin ﬁbroblasts were used for co-immunoprecipita-
tion assay.2. Materials and methods
2.1. Materials
Bikunin puriﬁed from human urine was kindly provided by Mochida
Pharmaceutical Co., Ltd. (Gotenba, Japan). Characterization of bik
and deglycosylated bik (chondroitin-4-sulfate-side chain deleted bik)
has been described previously [11]. Ultrapure natural human TGF-b1
was from Genzyme (Cambridge, MA) and R&D Systems (Minneap-
olis, MN). The antibodies against uPA (#3689 [recognizes the B-chain
of uPA] and #3471 [reacts with the A-chain of uPA; interferes with
binding of uPA to its receptor]) and PAI-1 (#3785) were obtained from
American Diagnostics, Greenwich, CT. Peroxidase-conjugated sec-
ondary antibodies were from Dako (Copenhagen, Denmark); antibody
to phospho-Smad2 was from Upstate Biotechnology (Lake Placid,
NY); antibodies to Smad2 and Smad3 were from Zymed Laboratories
(South San Francisco, CA); rabbit anti-TGF-bRI IgG (speciﬁc for
TGF-bRI p55) was from CosmoBio Co. Ltd., Tokyo, and rabbit anti-
TGF-bRII IgG (speciﬁc for TGF-bRII p70) was from Santa Cruz
Biotechnology, Santa Cruz, CA. Culture media, penicillin, strepto-
mycin, and fetal bovine serum (FBS) were purchased from Life
Technologies, Inc. Tissue culture plastics were purchased from Costar/
Corning (Cambridge, MA) and Falcon (Becton–Dickinson and Co.,
Bedford, MA). Bovine serum albumin (BSA), Tris–base, dithiothreitol
(DTT), phenylmethylsulfonyl ﬂuoride, and ammonium persulfate were
from Sigma Chemical Co., St. Louis, MO. Acrylamide, bisacrylamide,
and polyvinylidene diﬂuoride (PVDF) membrane were from Bio-Rad.
X-ray ﬁlm was purchased from Kodak Co. The enhanced chemilu-
minescence (ECL) was purchased from Amersham Pharmacia Biotech,
Tokyo, Japan. All other chemicals were, analytical grade.
2.2. Cell culture
The ovarian cancer cell lines, HRA [16] and SKOV-3 (American
Type Culture Collection), were grown in RPMI 1640 supplemented
with 10% (v/v) FBS, penicillin (100 units/ml), and streptomycin (100
lg/ml) in a 5% CO2 atmosphere with constant humidity. Human skin
ﬁbroblast strains were established from explants of human adult skin
biopsies obtained from informed healthy volunteers (age 32-40 years).
Cells were grown as monolayer cultures in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% FBS and 2 mM glutamine in the
presence of 5% CO2. Cells at subcultures 2–4 were used. Fibroblasts
were grown to subconﬂuency in 10% serum containing medium. TGF-
1 (10 ng/ml) was added either alone or in combination with test
compounds in cancer cells preincubated for 30 min to 1 h.2.3. Bikunin transfection
The bik expression vector pCMV-bik-IRES-bsr (Bikþ) and the
control vector pCMV-luciferase-IRES-bsr encoding luciferase (Lucþ)
were transfected into HRA cells by the standard calcium phosphate
precipitation method as described previously [16].
2.4. Preparation of cytosol and nuclear extracts
Cells were harvested, washed, and lysed in ice-cold lysis buﬀer (250
mM Tris–HCl, pH 7.5, containing a mixture of protease inhibitors [100
lg/ml phenylmethylsulfonyl ﬂuoride, 1 lg/ml E-64, 0.5 lg/ml leupep-
tin, and 1.7 lg/ml pepstatin A]). The debris was removed by centri-
fugation at 13 000g for 20 min at 4 C. Nuclear extracts were
prepared essentially as described [17]. Total protein amount in the
extracts was measured using the Bio-Rad Bradford reagent.
2.5. Western blot analysis
Cells were harvested and cell pellets were lysed as described above.
Centrifuged lysates (50 lg) from each cell were analyzed by SDS–
polyacrylamide gel electrophoresis and transferred to a PVDF mem-
brane by semi-dry transfer. Membranes were blocked for 1 h at room
temperature in Tris-buﬀered saline containing 0.1% Tween 20 and 2%
BSA. Blots were probed with the following primary antibodies over-
night at 4 C: monoclonal anti-uPA (#3689 plus #3471), anti-PAI-1,
anti-phospho-Smad2, anti-Smad2, or anti-Smad3 antibodies. This was
followed by incubation with the appropriate horseradish peroxidase-
conjugated secondary antibody at a dilution of 1:5000 for 1 h. De-
tection was achieved by enhanced chemiluminescence (Amersham
Pharmacia Biotech) and exposed to ﬁlm. Filters were quantitated by
scanning densitometry using a Bio-Rad model 620Video Densitometer
with a 1-d Analyst software package for Macintosh.
2.6. Northern blot hybridization with cDNA probes
Total RNA isolations were done using the Trizol reagent (Life
Technologies, Inc.). Northern blot hybridization was carried out as
described previously [10,18]. Samples of total RNA (10 lg) were sep-
arated by electrophoresis through denaturing 1.2% agarose gels con-
taining 1% formaldehyde and transferred onto nylon or nitrocellulose
membranes using standard molecular biological techniques. Hybrid-
ization was carried out with [a-32P]dCTP by random oligonucleotide
priming to speciﬁc activities of 0.4–0.9 109 cpm/lg. PAI-1 cDNA was
prepared as described [10,18]. Filters were reprobed with the cDNA for
glyceraldehyde-3-phosphate dehydrogenase to correct for the amount
of RNA loaded onto the ﬁlters [10,18]. After hybridization, the
membranes were washed and exposed on Kodak BioMax MS-1 ﬁlm at
)70 C.
2.7. Aﬃnity labeling and immunoprecipitation
Recombinant human TGF-b1 was iodinated using the chloramine T
method as described [19]. TGF-1 (1 lg) in 10 ll of 1 M sodium
phosphate, pH 7.2, was mixed with 2 ll of Na125I (0.2 lCi). The re-
action was initiated by the sequential addition of three 2-ll portions of
chloramine T (0.1 mg/ml). The reaction was stopped by the sequential
addition of 10 ll of acetyl tyrosine (100 mM), 100 ll of potassium
iodide (100 mM), and 100 ll of urea-saturated acetic acid.
For the cross-linking and immunoprecipitation experiments, sub-
conﬂuent cells in standard medium were rinsed once with KRH
binding buﬀer (50 mMHEPES, pH 7.5, 128 mMNaCl, 1.3 mM CaCl2,
and 5 mM MgSO4, 5 mM KCl) containing 50 pM
125I TGF-b1 (HRA
and SKOV-3 cells) or 200 pM 125I TGF-b1 (human skin ﬁbroblasts)
was added. Plates were incubated at 4 C with rotation for 2 h and then
rinsed three times with ice cold KRH. The plates were prepared in
duplicate; one half of the plate was treated with cross-linker and the
other half was untreated. The ligand was then cross-linked to the re-
ceptor with the addition of 0.5 mg/ml disuccinimidyl suberate (DSS)
(Pierce) from a 100-fold concentrated stock in DMSO, followed by
incubation at 4 C for 15 min. Glycine was added to 20 mM and plates
were incubated for 10 min at 4 C. In another plate, no cross-linker
was used. Plates were rinsed twice with ice-cold phosphate-buﬀered
saline (PBS) and lysed at 4 C for 20–30 min in 1 ml lysis buﬀer.
Cleared lysates were immunoprecipitated at 4 C overnight with
polyclonal antibodies against the TbRI or TbRII. One-twentieth vol-
ume of protein A–Sepharose CL-4B beads (Sigma) was added and the
lysates were incubated with rotation for 30 min. Protein A–Sepharose
beads were rinsed twice with lysis buﬀer and once with PBS and bound
protein was eluted by boiling in 0.5% SDS. Samples were analyzed by
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were visualized by autoradiography.
2.8. Procollagen deposition analysis by 3H proline incorporation,
SDS–polyacrylamide gel electrophoresis, and autoradiography
The parental and transfected cells were grown to subconﬂuency in
12-well plates. The medium was changed to serum-free medium sup-
plemented with 50 lg/ml ascorbic acid for the duration of the experi-
ment. Cells were stimulated with 10 ng/ml TGF-b1 and 6 h later, 0.5
lCi/ml 3H proline (Amersham Biosciences) was added to the medium
for 24 h. Medium was harvested from each well, and cells were
trypsinized and counted. Cells were lysed and extracellular matrix
proteins were ﬁxed in 70% ethanol. Collagen deposition was deter-
mined by diﬀerential collagenase digestion and liquid scintillation
counting [20].
2.9. Cell growth assay: thymidine incorporation
Cells were seeded into 24-well plates in the presence or absence of
TGF-b1 (10 ng/ml) for 16 h, as indicated. Cells were pulsed with 0.5
lCi/ml 3H thymidine (Amersham Bioscience) for 4 h, and incorpora-
tion of radioactive label into newly synthesized DNA was analyzed by
trichloroacetic acid precipitation and liquid scintillation counting.
2.10. Flow cytometric analysis
A single cell suspension (106/ml) was incubated with antibodies or
isotype control antibodies on ice for 1 h. Cells were washed three times
with washing buﬀer, and 2 ll of the primary antibody and 3 ll of
ﬂuorescein isothiocyanate-conjugated secondary antibody (Dako)
were added for 1 h on ice, respectively. Cells were analyzed in a
FACScan (Becton–Dickinson). At least 10 000 cells were analyzed per
sample in all experiments. All experiments were performed at least
twice.
2.11. Statistical analysis
The data presented are means of triplicate determinations in one
representative experiment unless stated otherwise. Data are presentedFig. 1. Bikunin inhibits TGF-b-induced PAI-1 gene expression in HRA cells.
(Lucþ) were stimulated with 10 ng/ml TGF-b1 for 12 h. (C) and (D) HRA c
side chain (deglyco-Bik) were stimulated with 10 ng/ml TGF-b1 for 12 h. P
panel; Western blot analysis) expression. Overexpression of bik gene or exog
TGF-b1. Results presented were obtained in triplicate and are representatives
scan are meansS.D. of three experiments. P < 0:05 vs lane 1; and P <as meansS.D. All statistical analyse were performed using Stat-
View for Macintosh. The Mann–Whitney U test was used for the
comparisons between diﬀerent groups. P less than 0.05 were considered
signiﬁcant.3. Results
3.1. Eﬀect of bik on TGF-b1-induced expression of PAI-1
mRNA and protein in HRA cells
We have previously studied TGF-b1 signaling in human
ovarian cancer HRA cells, which are highly responsive to
TGF-b1. Smad2 phosphorylation correlates closely with the
TGF-b1-induced PAI-1 expression [21]. In HRA cells, TGF-b1
induces upregulation of both uPA and PAI-1 expression
[11,12]. In contrast, SKOV-3 cells do not express PAI-1 as
opposed to uPA expression and can be seen in response to
TGF-b1.
In the present study, we asked whether the expression of bik
can inhibit TGF-b1–mediated biological eﬀects in HRA and
SKOV-3 cells. For that purpose, both cells were stably trans-
fected with the full-length wild-type bik cDNA (Bikþ) or with
a control luciferase cDNA (Lucþ) as described and then
treated with TGF-b1. In a parallel experiment, the cells were
pretreated with 1 lM bik or 1 lM deglycosylated bik and then
exposed to TGF-b1. TGF-b1 responsiveness in these cell lines
was initially analyzed by monitoring the upregulation of PAI-1
mRNA expression. As demonstrated in Fig. 1A and B, treat-
ment of parental HRA cells or Lucþ cells with 10 ng/ml TGF-
b1 for 12 h led to a signiﬁcant increase in the PAI-1 expression(A) and (B) HRA cells stably transfected with bik (Bikþ) or luciferase
ells pretreated with or without bik or bik lacking chondroitin-4-sulfate
AI-1 mRNA (upper panel; Northern blot analysis) and protein (lower
enous bik reduced PAI-1 mRNA and protein expression in response to
of three independent experiments. (B) and (D) Values of densitometric
0:05 vs lane 2.
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cantly reduced in the HRA cells transfected with bik (3.2-fold).
In a parallel experiment (Fig. 1C and D), 10 ng/ml TGF-b1
produced an increase (peak at 12 h) in the PAI-1 mRNA ex-
pression in HRA cells (lane 2). In cells pretreated with bik
(lane 3), no TGF-b1–induced increase of PAI-1 mRNA ex-
pression was seen. Instead, it was reduced by 65% as compared
to TGF-b1-stimulated HRA cells. No such eﬀect was seen
when exogenous deglycosylated bik was added to the cells
(lane 4). This suggests that chondroitin-4-sulfate side chain is
important in mediating the inhibitory eﬀect of bik. In our
previous study [16], we have shown that endogenously ex-
pressed or exogenously added bik had a similar inhibitory ef-
fect on uPA expression in HRA cells.
Next, we studied whether the above-mentioned changes of
the PAI-1 gene expression were also associated with changes in
the levels of PAI-1 protein. Therefore, we estimated, by Wes-
tern blot, the ratio of the optical density of the PAI-1 protein,
based on the b-actin protein band under control conditions
and after the administration of TGF-b1 in the bik transfected
cells (Fig. 1A and B) and in HRA cells pretreated with or
without bik or deglycosylated bik (Fig. 1C and D). The results
showed that TGF-b1 treatment had a signiﬁcant eﬀect on the
expression level of the 60-kDa band corresponding to PAI-1 in
TGF-b1-stimulated cells. We observed that bik signiﬁcantly
suppressed the upregulation of PAI-1 in TGF-b1-stimulated
cells. On the other hand, no such eﬀect was seen with degly-
cosylated bik. These data demonstrated that bik can inhibit
TGF-b1-dependent upregulation of PAI-1 expression at the
mRNA and protein levels.
3.2. Bikunin abrogates TGF-b1-dependent stimulation of
collagenous protein synthesis
In the second set of experiments, we tested whether bik
regulates extracellular matrix production in HRA cells in the
presence of TGF-b1 by utilizing bik transfectants. Lysates of
the cells metabolically labeled with 3H proline were analyzed.
Parental HRA cells and control cells expressing luciferase and
lacking endogenous bik demonstrated enhanced TGF-b1–in-
duced collagen deposition (Fig. 2A). In contrast, abrogation of
the stimulatory eﬀect of TGF-b1 on collagenous protein syn-
thesis by 70% was seen in bik-expressing cells, suggestingA
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Summary of quantitative analysis of the collagenous proteins expressed by
proliferation was analyzed by [3H] thymidine incorporation in pools of stably
presented as percentage of control (unstimulated proliferation). Experiments
two independent experiments. Values are meansS.D. of three independentsuppression of the TGF-b1–mediated collagen deposition by
bik (Fig. 2A). Moreover, addition of exogenous, but not de-
glycosylated bik to the cell culture also led to a diminished
TGF-b1-induced collagen deposition (data not shown). Bi-
kunin does not activate the degradative pathways (e.g., matrix
metalloproteinases) [16] making it highly unlikely that the
lowered amount of collagen would be due to enhanced deg-
radation [19]. Taken together, our results thus far demonstrate
that bik is a potent inhibitor of the TGF-b1 signaling as judged
by its eﬀect on TGF-1-regulated synthetic events.
HRA cells show no detectable growth response to TGF-b1
as shown in Fig. 2B. Neither did bik have any eﬀect on the
growth rate. Thus, overexpression of bik in cells did not aﬀect
cell viability or proliferation rate.
3.3. Bikunin inhibits TGF-b1-mediated Smad2 phosphorylation
and nuclear translocation of Smad3
In the TGF-b1 signaling pathway, phosphorylation of the
cytoplasmic signaling molecules Smad2 by TbRI is the ﬁrst
step in signal transduction. In the present study, we examined
whether TGF-b1 induces phosphorylation of Smad2 in HRA
(Fig. 3A and B, lanes 1–3) and SKOV-3 (lanes 10–12) cells by
Western blotting. In HRA cells, TGF-b1 induced a marked
rise in the level of phosphorylated Smad2 protein in a time-
dependent manner. As compared with the non-stimulated
HRA cells, an 8-fold increase in the phosphorylated Smad2
was observed at 20 min in response to 10 ng/ml TGF-b1.
Similar amounts of Smad2 protein were detected by anti-
Smad2 antibodies, irrespective of whether cells were stimulated
with TGF-b1 or not. On the other hand, TGF-b1 (10 ng/ml, 20
min) did not induce phosphorylation of Smad2 in SKOV-3
cells (lanes 10–12). HRA cells expressing bik demonstrated a
clear reduction in the TGF-b1-induced Smad2 phosphoryla-
tion (lanes 4–6) compared with the parental HRA cells (lanes
1–3), or HRA cells expressing luciferase (lanes 7–9). No change
in the total level of Smad2 was found in response to the ex-
pression of bik.
We next investigated the eﬀect of bik and TGF-b1 on the
nuclear translocation of Smad3 as an important signaling step
in TGF-b1 signaling pathway. An increase in nuclear translo-
cation was observed at 20 min in response to TGF-b1 (Fig. 3C
and D, lanes 1–4). HRA cells expressing bik demonstrated aB
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SDS–PAGE and probed with anti-phospho-Smad2 (0.5 lg/ml) to detect the phosphorylated Smad2 protein (top panel). Blots were stripped and
reprobed with anti-Smad2 antibody (0.5 lg/ml) (bottom panel). Experiments were repeated three times with essentially identical results. (B) Blots
were scanned and analyzed for quantiﬁcation with the Macintosh software. Band intensities for phospho-Smad2 were normalized to the corre-
sponding band intensities for total Smad2. Data from three experiments were averaged and are represented as meansS.D., expressed as fold
increase with respect to non-stimulated cells (time¼ 0). P < 0:05 vs lane 1; and P < 0:05 vs lane 2. (C) Nuclear translocation of Smad3 was
analyzed by immunoblotting with an antibody speciﬁc for total Smad3. Results shown are representatives of three independent experiments. (D)
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5–8) when compared with the parental HRA cells (lanes
1–4), or the HRA cells expressing luciferase (lanes 9–12). As
expected, no nuclear translocation of Smad3 was seen in
SKOV-3 cells upon TGF-b1-treatment (10 ng/ml, 20 min)
(lanes 13–16).
3.4. Exogenous bik inhibits TbRI-tbRII oligomerization
In a ﬁrst set of experiment, we assessed the eﬀect of bik on
the expression of TbRI and TbRII on the surface of HRA and
SKOV-3 cells by ﬂow cytometry. Cells were incubated with or
without TGF-1 (10 ng/ml, 12 h) in the presence or absence of
bik (1 lM). Non-immune mouse IgG was used as the control
IgG. Bikunin did not have any measurable eﬀect on the ex-
pression of TbRI and TRII, irrespective of whether cells were
stimulated with TGF-b1 (data not shown) or not.In order to demonstrate the speciﬁcity of the anti-TbRI and
anti-TbRII antibodies, we carried out immunoblotting. Cell
lysates of HRA (Fig. 4A, upper panel), SKOV-3 cells (Fig. 4A,
lower panel) and skin ﬁbroblast cells (data not shown) were
probed with anti-TbRI or anti-TbRII antibodies. The 55 kDa
and 70 kDa bands were detected by anti-TRI or anti-TbRII
antibodies, respectively (Fig. 4A). Following in vitro culture of
cells with TGF-b1, there were no signiﬁcant increases in cell
surface expression of TbRI and TbRII compared with the
unstimulated cells (data not shown).
We next studied whether bik inhibits TGF-b1 signaling in
HRA cells by inhibiting hetero- or oligomerization of TbRs as
has been shown to be the mechanism for bik-inhibited CD44-
mediated signaling [10]. For that purpose, the cells pretreated
with either bik or the vehicle (PBS) were aﬃnity-labeled with
125I TGF-b1. The cell lysates were then immunoprecipitated
Fig. 4. Bikunin inhibits heterodimer formation between TbRI and TbRII. (A) Cell lysates (50 ll) of HRA (upper panel) and SKOV-3 cells (lower
panel) were separated by SDS–PAGE, and speciﬁc bands were visualized using antibodies against TGF-b receptor type I or type II. Cells were
incubated with 10 ng/ml 125I TGF-b1 in the absence (B and C) or presence (D and E) of bik (1 lM). Cell lysates were immunoprecipitated with anti-
TbRI (upper panel) or anti-TbRII (lower panel) antibodies and eluted by boiling in 0.5% SDS. (F) Cells were labeled with 125I TGF-b1 for 20 min
and treated with (lane 2) or without (lane 1) the chemical cross-linker DSS. The DSS-treated or non-treated cells were lysed and the lysate was
immunoprecipitated with the anti-TbRI antibody. Immunoprecipitates were separated by SDS–PAGE and speciﬁc bands were visualized by au-
toradiography (C and E). Band intensities for TbRII were scanned. Data from three experiments were averaged and are represented as meansS.D.,
expressed as fold increase with respect to non-stimulated cells (time¼ 0). The positions of molecular mass markers (in kDa) are indicated on the right
margin. The blots shown are representatives of blots performed on samples from three diﬀerent experiments.  and #P < 0:05 vs lane 1.
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precipitations using anti-TbRI antibodies (Fig. 4B and C) re-
vealed that TGF–b1 stimulation for more than 10 min induced
an increase in the expression of the 90-kDa band in a time-
dependent manner. This protein species is equivalent to 70
kDa, the approximate molecular mass of the type II TGF-b
receptor (Fig. 1A), if the molecular mass of the bound mo-
nomeric TGF-b1 is subtracted. No TbRI band was seen in the
autoradiograms. This is because we did not use cross-linker
agent in this study and 125I labeled TGF-b1 directly binds to
TbRII but not to TbRI. In a parallel experiment with anti-
TbRII antibody, the 90-kDa band was consistently detected
by anti-TbRII antibody in response to 125I TGF-b1. This in-
dicates that the formation of TbRI and TbRII complexes can
be seen in cells in response to TGF-b1.
In the presence of bik, the formation of receptor complexes
was inhibited as seen when comparing the co-immunoprecip-
itation results in Fig. 4B and D. The 90-kDa monomeric
forms of TbRII in TGF-b1-stimulated cells migrate similarly
to that in unstimulated cells, irrespective of whether bik is used
in the experiments, suggesting that bik inhibits dramatically
the formation of receptor complexes. These above results
suggest that 125I TGF-b1 speciﬁcally binds to TbRII and that
TbRI and TbRII proteins are able to heteromerize under the
TGF-1 stimulation within at least 20 min, and that bik can
abrogate TGF-b1-stimulated complex formation of TbRI–
TbRII proteins.If the complex indeed dissociates into TbRI and TbRII upon
lysis of cells, chemical cross-linking may preserve its integrity
and thus reveal its presence in intact cells. We therefore labeled
cells with 125I TGF-b1 and treated them with the chemical
cross-linker DSS. The DSS-treated cells were lysed and the
lysate was immunoprecipitated with the anti-TbRI antibody.
A smear from 80 to 200 kDa appears as shown in Fig. 4F, lane
2. SDS–PAGE and autoradiography of control samples not
subjected to DSS treatment revealed that anti-TbRI antibody
brings down only the 125I TGF-b1 bound TbRII protein,
which lies within the molecular mass range of 80–90 kDa
(Fig. 4F, lane 1). With the DSS pretreatment, however, the
same immunoprecipitation procedure recovers many addi-
tional smear proteins. The majority of the proteins migrate at
the top of the gel, suggesting their association in a large
complex. Therefore, we did not use cross-linker agent for
further experiments using HRA and SKOV-3 cells.
Some alternative conﬁrmatory experiment would be needed
to directly resolve the fact that bik disrupts heterodimerization
of the TbRs on the cell surface. We have repeated the exper-
iments on another cell type where visualization of the cell
surface receptors is easier to detect. Such a cell type should also
be responsive to bik and it may not be an ovarian cell. Our
preliminary study demonstrated that 125I labeled TGF-b1
binds to TbRII as well as to TbRI in the human skin ﬁbroblast
cells. Interestingly, immunoprecipitations using cross-linker
DSS demonstrate the existence of TbRI–TbRII complexes. In
Fig. 6. Bikunin expression prevents TbRI/TbRII association in HRA
and SKOV-3 cells. Pools of HRA and SKOV-3 cells stably expressing
bik or luciferase were aﬃnity-labeled with 125I TGF-b1 (10 ng/ml) for 2
h at 4 C. Cell lysates were then prepared and immunoprecipitated
with antibodies against TbRI (A) or TbRII (B). Immunoprecipitates
were subjected to SDS–PAGE and autoradiography. In both cells,
TbRI–TbRII complexes are formed in response to TGF-b1. The
complexes are only observed in parental cells and cells expressing lu-
ciferase. Bikunin gene transfection abrogates TGF-b1-dependent
TbRI–TbRII association. The positions of molecular mass markers (in
kDa) are indicated on the right margin. The data shown are repre-
sentatives of results obtained in three independent experiments.
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ﬁbroblast cells to easily visualize the cell surface receptors. For
double immunoprecipitation experiments, aﬃnity-labeled ﬁ-
broblasts pretreated with or without bik (1 lM) were immu-
noprecipitated with antibodies against the TbRI or TbRII
(Fig. 5). Immunoprecipitations demonstrate the existence of
TbRI–TbRII complexes (lanes 1 and 2) in the absence of bik.
In cells treated with bik, however, TbRI and TbRII do not co-
immunoprecipitate, regardless of whether anti-type I or anti-
type II receptor antibodies are used. No labeled TbRI could be
detected by such co-immunoprecipitation experiments (lanes 4
and 5). It is of note that Western blot analysis revealed no
change in the total levels of TbRI and TbRII proteins (data
not shown).
3.5. Exogenously expressed bik inhibits association of
TbRI–TbRII induced by TGF-b1
Cells stably transfected with either bik or luciferase were
aﬃnity-labeled with 125I TGF-b1, for 2 h at 4 C, washed, and
the cell lysates were then immunoprecipitated with antibodies
against the two TGF-b receptors (Fig. 6). In the parental HRA
cells (lanes 1 and 2) or in the cells transfected with luciferase
(lanes 5 and 6), immunoprecipitation with antibodies
against TbRI (Fig. 6A) or TbRII (Fig. 6B) demonstrates co-
immunoprecipitation of the two receptors, suggesting the
presence of TbRI–TbRII complexes. Using anti-TbRI anti-
body, 125I TGF-b1-bound TbRII could be detected. In cells
expressing bik (lanes 3 and 4), however, TbRI and TbRII do
not co-immunoprecipitate. There was 90% reduction in the
TbRI–TbRII complex formation in bik-expressing cells when
compared with the parental HRA cells. On the other hand,
using anti-TbRII antibody (Fig. 6B), 125I TGF-b1-bound
TbRII could be detected either in the presence or absence of
bik. Bikunin did not seem to aﬀect 125I TGF-b1 binding to
TbRII. As shown in Fig. 6A, lanes 7 and 8, TGF-1 did induce
the TbRI–TbRII complex formation in the SKOV-3 cells. We
also conﬁrmed that bik inhibits association of TbRI–TbRII
induced by TGF-b1 in SKOV-3 cells (lanes 9 and 10). The
above results show that there is a signiﬁcant decrease in the
TbRI–TbRII complex formation in bik-expressing cells. ThisFig. 5. Bikunin prevents TbRI/TbRII association in human skin ﬁ-
broblast cells. Cells were aﬃnity-labeled with 125I TGF-b1 (200 pM)
for 2 h and cross-linked as described previously (19). Cell lysates were
then prepared and immunoprecipitated with antibodies against TbRI
(lanes 1 and 4), TbRII (lanes 2 and 5), or non-immune IgG (lanes 3
and 6). Immunoprecipitants were subjected to SDS–PAGE and auto-
radiography. TbRI–TRII complexes are only observed when cells were
not treated with bik. Lanes 3 and 6 represent the negative control. The
data shown are representatives of results obtained in three independent
experiments.provides a putative mechanistic explanation for the observed
decrease in phosphorylation of Smad2 and nuclear transloca-
tion of Smad3 (Fig. 3) and inhibition of TGF-b signaling in
these cells (Figs. 1 and 2). Deglycosylated bik lacks the in-
hibitory eﬀect on TGF-1 signaling (data not shown). These
data demonstrate that the high molecular weight chondroitin-
4-sulfate modiﬁcations of bik render it an inhibitory molecule
in TGF-b1 signaling. Immunoprecipitation with antibody
against bik demonstrated that there is no co-immunoprecipi-
tation of TbRI or TbRII and bik (data not shown). This
suggests that bik does not physiologically interact with TbRI
or TbRII.4. Discussion
We describe for the ﬁrst time a novel physiological eﬀect of
the Kunitz-type protease inhibitor bik against the normal
function of the TGF-b pathway in human ovarian cancer
HRA and SKOV-3 cells as well as in human skin ﬁbroblasts.
We explore the physiological eﬀect ﬁrst by focusing on the
regulation of PAI-1 and collagen synthesis, two well-estab-
lished physiological responses of many cell types to TGF-b.
Then, we aim at exploring and understanding the mechanism
by which bik might elicit its cellular eﬀects against the TGF-b
pathway. We present two possibilities: (1) bik might directly
interfere with the TGF-b pathway. As bik resides extracellu-
larly, it would make sense to explore mechanisms on the cell
surface that possibly interferes with proper TGF-b receptor
assembly and activation. (2) bik might initiate a signaling
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whose outcome, intracellularly would be antithetic to normal
TGF-b signal propagation.
We previously found that bik inhibits CD44 signaling by
preventing coupling CD44 molecules and that it forms mem-
brane complexes with binding protein/receptor and initiates
modulation of signal transduction, which results in bik-medi-
ated suppression of cell invasiveness [2–4,7,8,10]. We have
clearly demonstrated in the recent studies [10] that exogenous
bik forms aggregates (LP–bik–bik-R complex) on the cell
surface, that bik can disrupt complex formation of CD44
possibly through coupling between CD44 and bik-R on the
plasma membrane (we showed that deglycosylated bik does
not have the same eﬀect as the native bik), and that bik-R
requires bik for an association with CD44 molecules. This fact
suggests that coupling (heterodimer formation) of CD44 pro-
teins and bik-R is important for bik-mediated suppression of
signaling. However, a major problem that still remains is that
bik-R has not yet been identiﬁed [10]. Connection between
complex formation of TGF-b receptor proteins and PAI-1
expression is promising [22]. One may estimate that disruption
of the CD44-related oligomers with bik may be involved in
simultaneous decrease in the TbRI and TbRII coupling.
The present study strongly demonstrated that bik inhibits
rather dramatically the formation of TbRI and TbRII com-
plexes, thus explaining the inhibitory eﬀects on signal trans-
duction by this polypeptide factor. In the ovarian cancer cells,
however, one cannot directly visualize the TbRI–TbRII com-
plex protein band. We are willing to present the validity of the
co-immunoprecipitation data on another cell type where vi-
sualization of the cell surface receptors is easier to detect. To
better understand the function of bik, human skin ﬁbroblast
cells were used for further coimmunoprecipitation experi-
ments. There is increasing evidence [23] that these cells express
TbRI and TbRII and TGF-b modulates certain biological
functions. We clearly showed that bik disrupts heterodimer-
ization of the TbRs on the ﬁbroblast cell surface.
To more strengthen the evidence for a role of bik in dis-
rupting surface complexes between TGF-b1 and its two sig-
naling receptors, we need further experiments using transient
transfection of a constitutively active mutant TGF-b receptor.
We have been examining whether bik has an eﬀect on a
transfected mutant TbRI that is constitutively active and thus
bypasses the need of TGF-1 or TbRII. If the proposed model
is correct, bik should have no measurable eﬀect on such a
constitutively active mutant receptor.
Although the evidence for disruption of TGF-b receptor
complexes by bik is strong, it does not preclude the possibility
that bik could also signal via interaction with its own receptor
or CD44 in a manner that blocks TGF-b receptor signaling.
We have been examining the expression of Smad7 in cells
treated with bik or in the stable Bikþ clone, since Smad7 has
been shown to inhibit TGF-b signaling. cDNA microarray
analysis was performed on RNA from HRA cells incubated in
the presence or absence of TGF-b1 and bik for 24 and 48 h.
Bikunin opposed TGF-b1-regulated genes related to ﬁbrosis
(PAI-1, collagen, and ﬁbronectin), cell growth (PDGF, FGF,
and IGF), and inﬂammation (COX2 and TNF superfamily
member) (data not shown). These analyses also revealed that
exogenously added bik or bik gene transfection does not
activate Smad7 transcription in unstimulated or TGF-b1-
stimulated HRA cells [24]. Furthermore, immunoﬂuorescenceanalysis revealed that the inhibitory Smad, Smad7, was not
exported to the cytoplasm from the nucleus by the treatment
with bik (data not shown). Therefore, it is unlikely that bik
could mediate signals by direct regulation of an inhibitory
Smad like Smad7. Bikunin inhibits TGF-b signal transduction
by a mechanism rather than through the regulation of Smad7.
We cannot exclude the possibility, however, that bik regulates
a protein(s) that interacts with the cytoplasmic domain of the
TGF-b receptors or other downstream targets of these recep-
tors, which regulates TGF-b signaling.
We have also clearly demonstrated that bik chondroitin-4-
sulfate chains account for its inhibitory activity in cells because
deglycosylated bik did not aﬀect TGF-b1 signaling. Corre-
spondingly, deglycosylated bik had no eﬀect on TbRI/TbRII
association in co-immunoprecipitation assays. Similar to this
function, we have previously observed the inhibition of CD44
signaling in cells treated with bik, but not bik lacking its
chondroitin-4-sulfate side chain. Bikunin lacking chondroitin-
4-sulfate cannot disrupt the clustering of CD44 proteins, in-
dicating that the chondroitin-4-sulfate side chain of bik is
important to display its function [10]. Bikunin has two gly-
cosaminoglycan sites that have been shown to be speciﬁc for
either O-glycoside (chondroitin sulfate chain) or N-glycoside
side chain [25]. We have determined that chondroitin sulfate
chain is responsible for the eﬀects we see [25]. We are currently
investigating the structural basis for the glycosaminoglycan
eﬀect and the relative contributions of chondroitin sulfate
chain to bik function.
Besides TGF-b type I and type II receptors, TGF-b has two
known co-receptors, betaglycan and endoglin, which are
transmembrane glycoproteins with large extracellular regions
that bind TGF-b and small cytoplasmic regions without any
clearly identiﬁable signaling motif [26]. Betaglycan is a pro-
teoglycan and is a membrane proteoglycan containing heparan
and chondroitin sulfate chains, whose core protein binds all
three TGF-b isoforms [27]. Betaglycan is capable of ﬁne tuning
the availability of TGF-b to the signaling receptors, thereby
determining the outcome of the TGF-b stimulation [28]. In a
model that involves TGF-b receptors and CD44, the data at
this stage allow an alternative interpretation or model: it may
be possible that bik blocks access of betaglycan or endoglin to
the signaling receptors. Our preliminary data revealed that by
cDNA microarray analysis, HRA cells constitutively express
betaglycan [24]. However, binding of bik to the HRA cells was
not inhibited by neutralizing antibodies to betaglycan (un-
published data). It is thus unlikely that the role of bik might be
needed for complex formation with molecules such as beta-
glycan.
How general is the observed eﬀect of bik in terms of its cell
type speciﬁcity? The same inhibitory eﬀect against TGF-b can
be observed by addition of exogenous bik on other cell lines,
including HCS-2/8 human chondrosarcoma cells (data not
shown). These cells also expressed bik-R and CD44 proteins.
Thus, bik may be eﬀective in cells expressing these two bik
binding proteins.
Nothing is known about the molecular mechanism by which
direct bik coupling to TGF-b receptor proteins takes place.
Notwithstanding these limitations, this is the ﬁrst report
demonstrating the suppression of TGF-b1-induced expression
of PAI-1 mRNA and protein by bik possibly through inhibi-
tion of complex formation of TbRI and TbRII proteins on the
plasma membrane of tumor cells.
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